Teligent announced that the Food and Drug Administration (FDA) has approved its Abbreviated New Drug Application (ANDA) for Desoximetasone Ointment, the generic version of Taro‘s Topicort

Desoximetasone is a topical steroid indicated for corticosteroid-responsive dermatoses. Topical corticosteroids share anti-inflammatory, anti-pruritic, and vasoconstrictive actions. They play a role in cellular signaling, immune function, inflammation and protein regulation.

RELATED: Topical Steroid Potencies

Desoximetasone will be available as a 0.25% strength ointment in 15g, 60g, and 100g tubes. It is expected to launch in the second quarter of 2016. 

For more information call (856) 697-1441 or visit Teligent.com.